nach oben

Annals of Nuclear Medicine

Erschienen in:

01.05.2013 | Invited review article

A brief review of Japanese guidelines for the clinical use of ¹⁸F-FDG-PET/MRI 2012 (Ver 1.0)

verfasst von: Tomohiro Kaneta

Erschienen in: Annals of Nuclear Medicine | Ausgabe 4/2013

Einloggen, um Zugang zu erhalten

Abstract

This is a brief review of Japanese FDG-PET/MRI guidelines for indications, procedures, cautions for the interpretation of images, and safety management, which were created by a joint task force of the Japanese Radiologic Society, Japanese Society of Nuclear Medicine, and Japanese Society of Magnetic Resonance Imaging. The guidelines aim at the appropriate and effective use of the newly developed PET/MRI modality.

Nur mit Berechtigung zugänglich

Pichler BJ, Judenhofer MS, Wehrl HF. PET/MRI hybrid imaging: devices and initial results. Eur Radiol. 2008;18:1077–86.PubMedCrossRef

Boss A, Bisdas S, Kolb A, Hofmann M, Ernemann U, Claussen CD, et al. Hybrid PET/MRI of intracranial masses: initial experiences and comparison to PET/CT. J Nucl Med. 2010;51:1198–205.PubMedCrossRef

Boss A, Stegger L, Bisdas S, Kolb A, Schwenzer N, Pfister M, et al. Feasibility of simultaneous PET/MR imaging in the head and upper neck area. Eur Radiol. 2011;21:1439–46.PubMedCrossRef

Park H, Wood D, Hussain H, Meyer CR, Shah RB, Johnson TD, et al. Introducing parametric fusion PET/MRI of primary prostate cancer. J Nucl Med. 2012;53:546–51.PubMedCrossRef

Buchbender C, Heusner TA, Lauenstein TC, Bockisch A, Antoch G. Oncologic PET/MRI, part 1: tumors of the brain, head and neck, chest, abdomen, and pelvis. J Nucl Med. 2012;53:928–38.PubMedCrossRef

Buchbender C, Heusner TA, Lauenstein TC, Bockisch A, Antoch G. Oncologic PET/MRI, Part 2: bone tumors, soft-tissue tumors, melanoma, and lymphoma. J Nucl Med. 2012;53:1244–52.PubMedCrossRef

Drzezga A, Arnold S, Minoshima S, Noachtar S, Szecsi J, Winkler P, et al. 18F-FDG PET studies in patients with extratemporal and temporal epilepsy: evaluation of an observer-independent analysis. J Nucl Med. 1999;40:737–46.PubMed

Kim YK, Lee DS, Lee SK, Chung CK, Chung JK, Lee MC. 18F-FDG PET in localization of frontal lobe epilepsy: comparison of visual and SPM analysis. J Nucl Med. 2002;43:1167–74.PubMed

Savic I, Ingvar M, Stone-Elander S. Comparison of [11C]flumazenil and [18F]FDG as PET markers of epileptic foci. J Neurol Neurosurg Psychiatry. 1993;56:615–21.PubMedCrossRef

10.

Sasaki M, Kuwabara Y, Yoshida T, Fukumura T, Morioka T, Nishio S, et al. Carbon-11-methionine PET in focal cortical dysplasia: a comparison with fluorine-18-FDG PET and technetium-99 m-ECD SPECT. J Nucl Med. 1998;39:974–7.PubMed

11.

Knuuti J, Schelbert HR, Bax JJ. The need for standardisation of cardiac FDG PET imaging in the evaluation of myocardial viability in patients with chronic ischaemic left ventricular dysfunction. Eur J Nucl Med. 2002;29:1257–66.CrossRef

12.

Schelbert HR. 18F-deoxyglucose and the assessment of myocardial viability. Semin Nucl Med. 2002;32:60–9.PubMedCrossRef

13.

Okumura W, Iwasaki T, Toyama T, Iso T, Arai M, Oriuchi N, et al. Usefulness of fasting 18F-FDG PET in identification of cardiac sarcoidosis. J Nucl Med. 2004;45:1989–98.PubMed

14.

Koiwa H, Tsujino I, Ohira H, Yoshinaga K, Otsuka N, Nishimura M. Images in cardiovascular medicine: imaging of cardiac sarcoid lesions using fasting cardiac 18F-fluorodeoxyglucose positron emission tomography—an autopsy case. Circulation. 2010;122:535–6.PubMedCrossRef

15.

Ohira H, Tsujino I, Ishimaru S, Oyama N, Takei T, Tsukamoto E, et al. Myocardial imaging with 18F-fluoro-2-deoxyglucose positron emission tomography and magnetic resonance imaging in sarcoidosis. Eur J Nucl Med Mol Imaging. 2008;35:933–41.PubMedCrossRef

16.

Guidelines for clinical use of FDG PET, PET/CT 2012. Jpn J Nucl Med (Kaku Igaku). 2012;49:391–401. http://www.jsnm.org/guideline/20100330.

17.

Guidelines for clinical use of FDG PET, PET/CT 2010. Jpn J Nucl Med (Kaku Igaku). 2010;47:153–62

18.

Guidelines for PET Examination Using In-house-produced FDG (2nd Edition) (Japanese Society of Nuclear Medicine). Jpn J Nucl Med (Kaku Igaku). 2005;42:1–22. http://www.jsnm.org/files/pdf/guideline/fdg_guide2-2.pdf.

19.

Hofmann M, Steinke F, Scheel V, Charpiat G, Farquhar J, Aschoff P, et al. MRI-based attenuation correction for PET/MRI: a novel approach combining pattern recognition and atlas registration. J Nucl Med. 2008;49:1875–83.PubMedCrossRef

20.

Keereman V, Fierens Y, Broux T, De Deene Y, Lonneux M, Vandenberghe S. MRI-based attenuation correction for PET/MRI using ultrashort echo time sequences. J Nucl Med. 2010;51:812–8.PubMedCrossRef

21.

Pichler BJ, Kolb A, Nägele T, Schlemmer HP. PET/MRI: paving the way for the next generation of clinical multimodality imaging applications. J Nucl Med. 2010;51:333–6.PubMedCrossRef

22.

Malone IB, Ansorge RE, Williams GB, Nestor PJ, Carpenter TA, Fryer TD. Attenuation correction methods suitable for brain imaging with a PET/MRI scanner: a comparison of tissue atlas and template attenuation map approaches. J Nucl Med. 2011;52:1142–9.PubMedCrossRef

23.

CMR image acquisition protocols version 1.0: 2007. http://scmr.jp/mri/pdf/scmr_protocols_2007_jp.pdf.

24.

Morita N, Harada M, Otsuka H, Melhem ER, Nishitani H. Clinical application of MR spectroscopy and imaging of brain tumor. Magn Reson Med Sci. 2010;9:167–75.PubMedCrossRef

25.

Poptani H, Gupta RK, Roy R, Pandey R, Jain VK, Chhabra DK. Characterization of intracranial mass lesions with in vivo proton MR spectroscopy. AJNR. 1995;16:1593–603.PubMed

26.

Gerstner ER, Sorensen AG. Diffusion and diffusion tensor imaging in brain cancer. Semin Radiat Oncol. 2011;21:141–6.PubMedCrossRef

27.

Ellingson BM, Malkin MG, Rand SD, Connelly JM, Quinsey C, LaViolette PS, et al. Validation of functional diffusion maps (fDMs) as a biomarker for human glioma cellularity. J Magn Reson Imaging. 2010;31:538–48.PubMedCrossRef

28.

Romano A, Rossi Espagnet MC, Calabria LF, Coppola V, Figà Talamanca L, Cipriani V, et al. Clinical applications of dynamic susceptibility contrast perfusion-weighted MR imaging in brain tumours. Radiol Med. 2012;117:445–60.PubMedCrossRef

29.

Hayashi S, Ito K, Shimada M, Tsubuku M, Kaneko I, Kogure T, et al. Dynamic MRI with slow injection of contrast material for the diagnosis of pituitary adenoma. Radiat Med. 1995;13:167–70.PubMed

30.

Guidelines for PET Examination Using In-house-produced FDG (2nd Edition) (Japanese Society of Nuclear Medicine). Jpn J Nucl Med (Kaku Igaku). 2005;42:1–22.

31.

Guidelines for Safety Security in FDG-PET Examination (2005). Jpn J Nucl Med (Kaku Igaku). 2005;42:1–26.

32.

Guidelines for Imaging Techniques in FDG-PET Examination. Jpn J Nucl Med Technol (Kaku Igaku Gijutsu) 2007;27:425–56.

33.

Guidance for industry and FDA staff—Criteria for significant risk investigations of magnetic resonance diagnostic devices: U.S. Department of Health and Human Services, Food and Drug Administration, Center for Devices and Radiological Health. July 14, 2003.

34.

Shellock FG. The reference manual for magnetic resonance safety, implants and devices: 2008 eds. Biomedical Research Publishing Group, Los Angeles.

Titel: A brief review of Japanese guidelines for the clinical use of 18F-FDG-PET/MRI 2012 (Ver 1.0)
verfasst von: Tomohiro Kaneta
Publikationsdatum: 01.05.2013
Verlag: Springer Japan
Erschienen in: Annals of Nuclear Medicine / Ausgabe 4/2013
Print ISSN: 0914-7187
Elektronische ISSN: 1864-6433
DOI: https://doi.org/10.1007/s12149-013-0710-z

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 4/2013

Monitoring tumor proliferative response to radiotherapy using 18F-fluorothymidine in human head and neck cancer xenograft in comparison with Ki-67

Changes in 18F-fluorothymidine and 18F-fluorodeoxyglucose positron emission tomography imaging in patients with head and neck cancer treated with chemoradiotherapy

Symptomatic late-onset sialadenitis after radioiodine therapy in thyroid cancer

FDG PET/CT evaluation of pathologically proven pulmonary lesions in an area of high endemic granulomatous disease

Validation of novel calibration scheme with traceable point-like 22Na sources on six types of PET scanners

Discordance in the anatomical locations between morphological and perfusion changes occurring with the progression of Alzheimer’s disease